ARTICLE | Company News
Allergan, AZ partner to develop antibiotic
January 30, 2016 2:46 AM UTC
Allergan plc (NYSE:AGN) said it partnered with AstraZeneca plc (LSE:AZN; NYSE:AZN) to develop ATM-AVI, a combination of antibiotics aztreonam and avibactam to treat Gram-negative infections.
ATM-AVI was developed under a partnership between AZ and the U.S. Biomedical Medical Advanced Research and Development Authority (BARDA). Allergan said EU's Innovative Medicines Initiative (IMI) is supporting a European Phase II trial of the candidate, and will join BARDA and AZ in supporting Phase III development. ...